Clinical experience with the fourth generation cephalosporins

Area of Science:

• Pharmacology and Infectious Diseases
• Antimicrobial Therapy
• Clinical Microbiology

Background:

• Cefepime and cefpirome are fourth-generation cephalosporin antibiotics.
• Their clinical efficacy and bacteriological effectiveness are under review.
• Comparative data against other cephalosporins are essential for treatment guidelines.

Purpose of the Study:

• To review and synthesize evidence on the clinical and bacteriological effectiveness of cefepime and cefpirome.
• To compare their therapeutic success rates with established antibiotics like ceftazidime, cefotaxime, and ceftriaxone.
• To highlight necessary precautions for the clinical use of cefepime and cefpirome.

Main Methods:

• Review of comparative and non-comparative studies.
• Analysis of clinical and bacteriological success rates across various infection types.
• Synthesis of data on treatment outcomes in diverse patient populations, including neutropenic hosts.

Main Results:

• Both cefepime and cefpirome demonstrate high clinical and bacteriological efficacy, with success rates around 90%.
• Effective in treating complicated urinary tract infections, lower respiratory tract infections (community and nosocomial), skin/soft-tissue infections, surgical infections, and infections in neutropenic patients.
• These cephalosporins show cure rates similar to or better than ceftazidime, cefotaxime, and ceftriaxone.
• Penicillin-resistant Streptococcus pneumoniae infections were successfully treated.

Conclusions:

• Cefepime and cefpirome are highly effective antimicrobial agents for a broad spectrum of bacterial infections.
• Their efficacy is comparable or superior to other third-generation cephalosporins, offering a valuable therapeutic option.
• Clinical use requires adherence to specific precautions to ensure optimal outcomes and minimize risks.